Peer reviewed Publications 2015 – Current

  1. Reiling J, Forrest E, Bridle K, Britton L, Santrampurwala N, Crawford D, Dejong C, Fawcett J. Increased liver non-use: The implications of the shift towards Donation after Circulatory Death in Australia, 2017, In Press, Transplantation Direct.
  2. Forrest E, Reiling J, Lipka G and Fawcett J. Risk factors and clinical indicators for the development of biliary strictures post liver transplant: Significance of bilirubin. 2017, In Press, World Journal of Transplantation.
  3. Wang H, Thorling CA, Xu ZP, Crawford DHG, Liang X, Liu X, Roberts MS. Visualization and Modeling of the In Vivo Distribution of Mesenchymal Stem Cells. Curr Protoc Stem Cell Biol. 2017 Nov 15;43:2B.8.1-2B.8.17. doi: 10.1002/cpsc.39.
  4. Dixon J, Ong SY, Gurrin L, Nicoll A, Wolthuisen M, Wood E, Anderson G, Ramm G, Allen K, Olynyk J, Crawford DHG, Ramm L, Gow P, Durrant S, Powell L. A multi-centre participant-blinded randomised controlled trial of reduction of body iron in individuals with HFE-related haemochromatosis and moderate iron overload. The Lancet Haematology, 2017, In Press
  5. Alqahtani S, Ozaras R, Isakov V, Wyles D, Ferenci P, Feld JJ, Calinas F, Gschwantler M, Gane E, Crawford D, Jacobson IM, Dumas EO, King M, Sulkowski M: Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin. J Viral Hepat 2017, 24:280-6.
  6. Heritage M, Jaskowski L, Bridle K, Campbell C, Briskey D, Britton L, Fletcher L, Vitetta L, Subramaniam VN, Crawford D: Combination curcumin and vitamin E treatment attenuates diet-induced steatosis in Hfe-/- mice. World J Gastrointest Pathophysiol 2017, 8:67-76.
  7. Lee AS, van Driel ML, Crawford DH: The cost of successful antiviral therapy in hepatitis C patients: a comparison of IFN-free versus IFN-based regimens at an individual patient level in Australia. Clinicoecon Outcomes Res 2017, 9:595-607
  8. McLeay SC, Harvey WM, Romaniuk MN, Crawford DH, Colquhoun DM, Young RM, Dwyer M, Gibson JM, O’Sullivan RA, Cooksley G, Strakosch CR, Thomson RM, Voisey J, Lawford BR: Physical comorbidities of post-traumatic stress disorder in Australian Vietnam War veterans. Med J Aust 2017, 206:251-7.
  9. Reiling J, Bridle KR, Gijbels M, Schaap FG, Jaskowski L, Santrampurwala N, Britton LJ, Campbell CM, Olde Damink SW, Crawford DH, Dejong CH, Fawcett J: Low-Dose Lipopolysaccharide Causes Biliary Injury by Blood Biliary Barrier Impairment in a Rat Hepatic Ischemia/Reperfusion Model. Liver Transpl 2017, 23:194-206.
  10. Reiling J, Bridle KR, Schaap FG, Jaskowski L, Santrampurwala N, Britton LJ, Campbell CM, Jansen PLM, Damink S, Crawford DHG, Dejong CHC, Fawcett J: The role of macrophages in the development of biliary injury in a lipopolysaccharide-aggravated hepatic ischaemia-reperfusion model. Biochim Biophys Acta 2017.
  11. Wang H, Liang X, Gravot G, Thorling CA, Crawford DH, Xu ZP, Liu X, Roberts MS: Visualizing liver anatomy, physiology and pharmacology using multiphoton microscopy. J Biophotonics 2017, 10:46-60.
  12. Wang H, Zhang R, Bridle KR, Jayachandran A, Thomas JA, Zhang W, Yuan J, Xu ZP, Crawford DH, Liang X, Liu X, Roberts MS: Two-photon dual imaging platform for in vivo monitoring cellular oxidative stress in liver injury. Sci Rep 2017, 7:45374.
  13. Wood MJ, Crawford DHG, Wockner LF, Powell LW, Ramm GA: Serum ferritin concentration predicts hepatic fibrosis better than hepatic iron concentration in human HFE-Haemochromatosis. Liver Int 2017, 37:1382-8.
  14. Briskey D, Heritage M, Jaskowski LA, Peake J, Gobe G, Subramaniam VN, Crawford D, Campbell C, Vitetta L: Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. Therap Adv Gastroenterol 2016, 9:463-72.
  15. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Al-Mahtab M, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK: APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing. Hepatol Int 2016, 10:681-701.
  16. Omata M, Kanda T, Wei L, Yu ML, Chuang WL, Ibrahim A, Lesmana CR, Sollano J, Kumar M, Jindal A, Sharma BC, Hamid SS, Dokmeci AK, Mamun Al M, McCaughan GW, Wasim J, Crawford DH, Kao JH, Yokosuka O, Lau GK, Sarin SK: APASL consensus statements and recommendation on treatment of hepatitis C. Hepatol Int 2016, 10:702-26.
  17. Wang H, Liang X, Xu ZP, Crawford DH, Liu X, Roberts MS: A physiologically based kinetic model for elucidating the in vivo distribution of administered mesenchymal stem cells. Sci Rep 2016, 6:22293.
  18. Adams LA, Crawford DH, St Pierre TK, Olynyk JK: Reply: To PMID 25524401. Hepatology 2015, 62:1921-2.
  19. Adams LA, Crawford DH, Stuart K, House MJ, St Pierre TG, Webb M, Ching HL, Kava J, Bynevelt M, MacQuillan GC, Garas G, Ayonrinde OT, Mori TA, Croft KD, Niu X, Jeffrey GP, Olynyk JK: The impact of phlebotomy in nonalcoholic fatty liver disease: A prospective, randomized, controlled trial. Hepatology 2015, 61:1555-64.
  20. Bridle KR, Sobbe AL, de Guzman CE, Santrampurwala N, Jaskowski LA, Clouston AD, Campbell CM, Nathan Subramaniam V, Crawford DH: Lack of efficacy of mTOR inhibitors and ACE pathway inhibitors as antifibrotic agents in evolving and established fibrosis in Mdr2(-)/(-) mice. Liver Int 2015, 35:1451-63.
  21. Clark PJ, Stuart KA, Leggett BA, Crawford DH, Boyd P, Fawcett J, Whiteman DC, Baade PD: Remoteness, race and social disadvantage: disparities in hepatocellular carcinoma incidence and survival in Queensland, Australia. Liver Int 2015, 35:2584-94.
  22. Liang X, Grice JE, Zhu Y, Liu D, Sanchez WY, Li Z, Crawford DH, Le Couteur DG, Cogger VC, Liu X, Xu ZP, Roberts MS: Intravital multiphoton imaging of the selective uptake of water-dispersible quantum dots into sinusoidal liver cells. Small 2015, 11:1711-20.
  23. Lim SG, Amarapurkar DN, Chan HL, Crawford DH, Gane EJ, Han KH, Ahn SH, Jafri W, Jia J, Kao JH, Lesmana LA, Lesmana CR, Mohamed R, Phiet PH, Piratvisuth T, Sarin SK, Sollarno JD, Eguchi Y, Mahtab MA, Lee KH: Reimbursement policies in the Asia-Pacific for chronic hepatitis B. Hepatol Int 2015, 9:43-51.
  24. McDonald CJ, Ostini L, Wallace DF, Lyons A, Crawford DH, Subramaniam VN: Next-generation sequencing: Application of a novel platform to analyze atypical iron disorders. J Hepatol 2015, 63:1288-93.
  25. Omata M, Kanda T, Yokosuka O, Crawford D, Al-Mahtab M, Wei L, Ibrahim A, Lau GK, Sharma BC, Hamid SS, Chuang WL, Dokmeci AK: Features of hepatitis C virus infection, current therapies and ongoing clinical trials in ten Asian Pacific countries. Hepatol Int 2015, 9:486-507.
  26. Ong SY, Dolling L, Dixon JL, Nicoll AJ, Gurrin LC, Wolthuizen M, Wood EM, Anderson GJ, Ramm GA, Allen KJ, Olynyk JK, Crawford D, Kava J, Ramm LE, Gow P, Durrant S, Powell LW, Delatycki MB: Should HFE p.C282Y homozygotes with moderately elevated serum ferritin be treated? A randomised controlled trial comparing iron reduction with sham treatment (Mi-iron). BMJ Open 2015, 5:e008938.
  27. Reiling J, Lockwood DS, Simpson AH, Campbell CM, Bridle KR, Santrampurwala N, Britton LJ, Crawford DH, Dejong CH, Fawcett J: Urea production during normothermic machine perfusion: Price of success? Liver Transpl 2015, 21:700-3.
  28. Sobbe A, Bridle KR, Jaskowski L, de Guzman CE, Santrampurwala N, Clouston AD, Campbell CM, Subramaniam VN, Crawford DH: Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox. J Gastroenterol Hepatol 2015, 30:638-45.
  29. Thorling CA, Jin L, Weiss M, Crawford D, Liu X, Burczynski FJ, Liu D, Wang H, Roberts MS: Assessing steatotic liver function after ischemia-reperfusion injury by in vivo multiphoton imaging of fluorescein disposition. Drug Metab Dispos 2015, 43:154-62.
  30. Wang H, Liang X, Mohammed YH, Thomas JA, Bridle KR, Thorling CA, Grice JE, Xu ZP, Liu X, Crawford DH, Roberts MS: Real-time histology in liver disease using multiphoton microscopy with fluorescence lifetime imaging. Biomed Opt Express 2015, 6:780-92.

Reviews and Editorials

  1. Michel Fausther, Michele T. Pritchard, Yury V. Popov, and Kim Bridle, “Contribution of Liver Nonparenchymal Cells to Hepatic Fibrosis: Interactions with the Local Microenvironment,” BioMed Research International, vol. 2017, Article ID 6824762, 4 pages, 2017. doi:10.1155/2017/6824762.
  2. Britton LJ, Subramaniam VN, Crawford DH. Iron and non-alcoholic fatty liver disease. World J Gastroenterol 2016;22:8112-8122.
  3. H Wang, CA Thorling, X Liang, KR Bridle, JE Grice, Y Zhu, DHG Crawford, Z Ping Xu, X Liu and MS Roberts (2015). Diagnostic imaging and therapeutic application of nanoparticles targeting the liver. Journal of Materials Chemistry B, 3: 939–958.